Pre-order Enquiry
Request Free Sample
Investigation Report on China's Omeprazole Market, 2018-2022
SKU ID : CRI-13308375 | Publishing Date : 25-Oct-2018 | No. of pages : 30
Request Sample
Request Customization
Check Discounts
Description
Gastric ulcer is a common disease worldwide. It is estimated that there are 25 million to 70 million gastric ulcer patients in China.
As early as the 1980s, the global market size of gastric ulcer drugs exceeded USD 8 billion. In 1988, Swedish company Astra (now known as AstraZeneca) developed a new anti-ulcer drug — proton pump inhibitor Omeprazole (trade name: Losec). Omeprazole, able to inhibit gastric acid secretion and relieve gastralgia, gastrectasia and other symptoms in a short period of time, became popular among ulcer patients immediately after it was marketed. At the end of the 20th century, the annual sales value of Omeprazole once hit a record high of USD 6.26 billion.
Chinese pharmaceutical companies began to imitate Omeprazole API in 1992, after which a large number of generic drugs were put on the market. With the launch of generic Omeprazole in China, Chinese pharmaceutical companies keep scrambling for market share from AstraZeneca. Overall, the market size of Omeprazole in China is growing, with the sales value exceeding CNY 1.3 billion in 2017. Although there are many anti-ulcer drugs on the market, because of good effects, Omeprazole stands out from its many competitors and secures its leading role. As the lifestyle changes, the number of patients with gastric ulcer continues to rise in China. In the next few years, Omeprazole will still have certain growth potential in China.
Topics Covered:
- Situation of gastric ulcer in China
- Sales of Omeprazole in China
- Competition on China's Omeprazole market
- Major Omeprazole manufacturers in China
- Prices of Omeprazole in China
- Prospect of China's Omeprazole market from 2018 to 2022
Gastric ulcer is a common disease worldwide. It is estimated that there are 25 million to 70 million gastric ulcer patients in China.
As early as the 1980s, the global market size of gastric ulcer drugs exceeded USD 8 billion. In 1988, Swedish company Astra (now known as AstraZeneca) developed a new anti-ulcer drug — proton pump inhibitor Omeprazole (trade name: Losec). Omeprazole, able to inhibit gastric acid secretion and relieve gastralgia, gastrectasia and other symptoms in a short period of time, became popular among ulcer patients immediately after it was marketed. At the end of the 20th century, the annual sales value of Omeprazole once hit a record high of USD 6.26 billion.
Chinese pharmaceutical companies began to imitate Omeprazole API in 1992, after which a large number of generic drugs were put on the market. With the launch of generic Omeprazole in China, Chinese pharmaceutical companies keep scrambling for market share from AstraZeneca. Overall, the market size of Omeprazole in China is growing, with the sales value exceeding CNY 1.3 billion in 2017. Although there are many anti-ulcer drugs on the market, because of good effects, Omeprazole stands out from its many competitors and secures its leading role. As the lifestyle changes, the number of patients with gastric ulcer continues to rise in China. In the next few years, Omeprazole will still have certain growth potential in China.
Topics Covered:
- Situation of gastric ulcer in China
- Sales of Omeprazole in China
- Competition on China's Omeprazole market
- Major Omeprazole manufacturers in China
- Prices of Omeprazole in China
- Prospect of China's Omeprazole market from 2018 to 2022
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
